Chunxue Wang
A5101613294- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Stroke Rehabilitation and Recovery
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Neurological Disease Mechanisms and Treatments
- Intracerebral and Subarachnoid Hemorrhage Research
- Lipoproteins and Cardiovascular Health
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Traumatic Brain Injury and Neurovascular Disturbances
- Dementia and Cognitive Impairment Research
- Neurological Disorders and Treatments
- Neurological and metabolic disorders
- Cardiovascular Health and Disease Prevention
- Intracranial Aneurysms: Treatment and Complications
- Neuroinflammation and Neurodegeneration Mechanisms
- Blood Pressure and Hypertension Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Cancer-related molecular mechanisms research
- Advanced Neuroimaging Techniques and Applications
- Healthcare Systems and Practices
- Extracellular vesicles in disease
Beijing Tian Tan Hospital
2016-2025
Capital Medical University
2016-2025
First Affiliated Hospital of Jinan University
2016-2025
University of Science and Technology of China
2024-2025
Hefei Institutes of Physical Science
2024-2025
High Magnetic Field Laboratory
2024-2025
Harbin University of Science and Technology
2025
Shanghai East Hospital
2021-2025
Beijing Institute of Neurosurgery
2016-2025
Neuroscience Institute
2025
Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than alone.In randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours onset of high-risk TIA to combination (clopidogrel an initial dose 300 mg, followed by 75 mg per day for 90 days, plus 21 days) placebo...
We aimed to establish the prevalence, characteristics, and outcomes of intracranial atherosclerosis (ICAS) in China by a large, prospective, multicenter study. evaluated 2864 consecutive patients who experienced an acute cerebral ischemia<7 days after symptom onset 22 Chinese hospitals. All underwent magnetic resonance angiography, with measurement diameter main arteries. ICAS was defined as ≥50% reduction on angiography. The prevalence 46.6% (1335 patients, including 261 coexisting...
China faces the greatest challenge from stroke in world. The death rate for cerebrovascular diseases was 149.49 per 100 000, accounting 1.57 million deaths 2018. It ranked third among leading causes of behind malignant tumours and heart disease. age-standardised prevalence incidence 2013 were 1114.8 000 population 246.8 person-years, respectively. According to Global Burden Disease Study 2017, years life lost (YLLs) increased by 14.6%; YLLs due rose highest all 1990 2017. absolute numbers...
Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated clopidogrel.To estimate clopidogrel-treated attack.Three major alleles (*2, *3, *17) were genotyped among 2933 Chinese from 73 sites who enrolled in Clopidogrel High-Risk Patients Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted January 2, 2010, to March 20, 2012.Patients acute treatment clopidogrel...
Background As a leading cause of severe disability and death, stroke places an enormous burden on the health care system in China. There are limited data pattern current medical practice quality delivery for patients at national level. Aim The nation-wide prospective registry, China National Stroke Registry, will be considered with regard to its design, progress, geographic coverage, hospital patient characteristics. Methods Between September 2007 August 2008, Registry recruited consecutive...
China faces the greatest challenge from stroke in world. According to results Global Burden of Disease Study 2019, there were 3.94 million new cases, 28.76 prevalent cases and 2.19 deaths due 2019. Furthermore, is also leading cause disability-adjusted life-year (DALY) China, number DALYs reached 45.9 Several recent large-scale epidemiological surveys have updated data on pre-existing conditions contributed stroke. The age-adjusted prevalence overweight among Chinese adults aged 18–69 years...
Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Previous studies showed an inverse association between ideal cardiovascular health (CVH) metrics and the total risk of diseases stroke. This study aimed to investigate relationship CVH risks ischemic hemorrhagic stroke, respectively.We collected information on 7 (including smoking status, body mass index, dietary intake, physical activity, blood pressure, cholesterol, fasting glucose) among 91 698 participants from Kailuan study, China (72 826 men 18 872 women ages 98 years), free myocardial...
Background— The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases 90-day risk stroke without increasing hemorrhage comparison alone, but provided insufficient data to establish whether benefit persisted over a longer period time beyond termination. We report 1-year follow-up outcomes this trial. Methods Results— was randomized, double-blind, placebo-controlled conducted at...
<h3>Objective:</h3> We aimed to investigate whether the efficacy and safety of clopidogrel plus aspirin vs alone were consistent between patients with without intracranial arterial stenosis (ICAS), in Clopidogrel High-Risk Patients Acute Non-disabling Cerebrovascular Events (CHANCE) trial. <h3>Methods:</h3> assessed interaction treatment effects 2 antiplatelet therapies among ICAS, identified by magnetic resonance angiography (MRA) CHANCE (ClinicalTrials.gov identifier NCT00979589)....
Designing translational antioxidative agents that could scavenge free radicals produced during reperfusion in brain ischemia stroke and alleviate neurologic damage is the main objective for ischemic treatment. Herein, we explored simply synthesized a biomimic Mn3O4 nanoenzyme (HSA-Mn3O4) to constrain reperfusion-induced nervous system injury. This nanosystem exhibits reduced levels of inflammation prolonged circulation time potent ROS scavenging activities. As expected, HSA-Mn3O4 effectively...
Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects antioxidant anti-inflammatory in animal models. The present clinical trial aimed at testing the dexborneol versus on 90-day functional outcome patients acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III was conducted 48 hospitals China between May 2015 December...
The development of multifunctional injectable adhesive hydrogels with self-healing capacity, shape adaptability, on-demand removability, and excellent photothermal antibacterial activity to promote bacteria-infected wound healing is highly recommended in practical applications. In this work, an multiple-dynamic-bond crosslinked hydrogel was formed by a network dynamic borate/didiol interactions, hydrogen bonding, Schiff base bond. introduction Mussel-inspired catechol groups into the could...
Tirofiban is a highly selective nonpeptide antagonist of glycoprotein IIb/IIIa receptor, which reversibly inhibits platelet aggregation. It remains uncertain whether intravenous tirofiban effective to improve functional outcomes for patients with large vessel occlusion ischemic stroke undergoing endovascular thrombectomy.To assess the efficacy and adverse events before thrombectomy acute secondary occlusion.This investigator-initiated, randomized, double-blind, placebo-controlled trial was...
Background: Acute ischemic stroke (AIS) is a leading cause of disability and mortality worldwide. Prediction penumbra existence after AIS crucial for making decision on reperfusion therapy. Yet fast, inexpensive, simple, noninvasive predictive biomarker the poststroke with clinical translational potential still lacking. We aim to investigate whether CircOGDH (circular RNA derived from oxoglutarate dehydrogenase) in patients its role neuronal damage. Methods: was screened middle cerebral...
DL-3-n-butylphthalide (NBP) is a drug for treating acute ischemic stroke and may play neuroprotective role by acting on multiple active targets. The efficacy of NBP in patients with receiving reperfusion therapy remains unknown. To assess the safety intravenous thrombolysis and/or endovascular treatment. This multicenter, double-blind, placebo-controlled, parallel randomized clinical trial was conducted 59 centers China 90-day follow-up. Of 1236 stroke, 1216 18 years older diagnosed National...
Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding effectiveness tenecteplase beyond limited.
Background and Purpose— Little is known about intravenous recombinant tissue plasminogen activator (rtPA) use in China. By accessing the Chinese National Stroke Registry (CNSR), rate of rtPA was reviewed. We specifically examined issues prehospital in-emergency department delay compared them with published data from developed countries. Methods— Funded by government, CNSR only nationwide stroke registry that includes 132 urban hospitals. All patients eligible for were included analysis. then...
Abstract Glucagon-like peptide-1 (GLP-1) is an incretin hormone that increases glucose-dependent insulin secretion to reduce the glucose level. Liraglutide, a long-acting GLP-1 analogue, has been found have neuroprotective action in various experimental models. However, protective mechanisms of liraglutide ischaemic stroke remain unclear. Here, we demonstrated significantly decreased infarct volume, improved neurologic deficits and lowered stress-related hyperglycaemia without causing...
Background and Purpose— Diabetes mellitus (DM) is an independent risk factor for ischemic stroke. However, controversy exists with regard to the impact of DM on prognosis after stroke in Chinese population. We investigated associations between death, dependency, recurrence patients onset a nationwide, prospective registry, China National Stroke Registry. Methods— The Registry consecutively recruited hospitalized acute 2007 2008 who were prospectively followed up clinical functional outcomes...